Maze Therapeutics, Inc. Common Stock (MAZE) — Cash Flow-to-Debt Ratio
Maze Therapeutics, Inc. Common Stock (MAZE) has a Cash Flow-to-Debt Ratio of -0.19x as of June 2026, meaning its operating cash flow of $-15.05 Million could theoretically repay 0% of its total liabilities ($78.50 Million) in one year. See how financially flexible is Maze Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Maze Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Maze Therapeutics, Inc. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see Maze Therapeutics, Inc. Common Stock (MAZE) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Maze Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Maze Therapeutics, Inc. Common Stock. Check MAZE operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.66x | $-111.94 Million | $42.16 Million | ▼ -252.5% |
| 2024 | 1.74x | $75.95 Million | $43.64 Million | ▲ +223.2% |
| 2023 | -1.41x | $-86.83 Million | $61.45 Million | ▲ +30.9% |
| 2022 | -2.04x | $-99.20 Million | $48.51 Million | — |